SCHEDULE: J. Wood Capital Advisors Discloses 4.99% Stake in Karyopharm

J. Wood Capital Advisors LLC and Jason Wood have disclosed a 4.99% beneficial ownership stake in Karyopharm Therapeutics Inc., totaling 1,000,708 shares.

Summary

• J. Wood Capital Advisors LLC and Jason Wood collectively hold beneficial ownership of 1,000,708 shares of Karyopharm Therapeutics Inc. Common Stock.
• This ownership represents 4.99% of the outstanding Common Stock of Karyopharm Therapeutics Inc.
• The beneficial ownership is based on 15,926,939 shares of Common Stock outstanding as of October 14, 2025.
• The reported share amounts reflect a 1-for-15 reverse stock split effected by Karyopharm Therapeutics Inc. on February 24, 2025.
• J. Wood Capital Advisors LLC is the record holder of 784,802 shares of Common Stock and 215,906 warrants.
• The warrants contain a provision preventing exercise if it would result in the Reporting Persons beneficially owning greater than 4.99% of the outstanding Common Stock.
• Jason Wood, as the managing member of J. Wood Capital Advisors LLC, is deemed to share beneficial ownership of these shares.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, nor in connection with any transaction having that purpose, other than activities solely related to a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: This is a routine disclosure of beneficial ownership, indicating a passive investment stake. It does not inherently convey positive or negative sentiment regarding the company's performance or prospects, but rather a factual reporting of an investment position.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing indicates a significant, but non-controlling, investment by J. Wood Capital Advisors LLC and Jason Wood in Karyopharm Therapeutics Inc., a biotechnology company. Such disclosures are common for institutional investors taking passive stakes below the 5% threshold that would trigger more extensive reporting requirements (e.g., Schedule 13D, which implies intent to influence management).

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be viewed as a vote of confidence or simply a portfolio allocation. The 4.99% stake is just below the 5% threshold that would require more active disclosure, suggesting a passive investment strategy.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not contain information that would fundamentally alter the investment thesis for Karyopharm Therapeutics Inc. It merely confirms an existing, passive stake by J. Wood Capital Advisors LLC and Jason Wood. Therefore, a 'hold' recommendation is appropriate, as the filing itself provides no new catalysts for a 'buy' or 'sell' decision, but rather confirms an investor's position.

Keywords

Karyopharm Therapeutics, J. Wood Capital Advisors, Jason Wood, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals, Investment, Equity Stake